



Citi Pharma Limited

February 13, 2026

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.

Financial results for the half year ended December 31, 2025

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on Friday, February 13, 2026 at 1:30 Pm 588 Block Q, Phase 2 Johar Town, Lahore Lahore have Recommended the following.

- | | |
|---|-----|
| 1. Cash Dividend | Nil |
| 2. Bonus Shares | Nil |
| 3. Right Shares | Nil |
| 4. Any other entitlement/corporate action | Nil |
| 5. Any other Price sensitive information | Nil |

Statement of Financial Position, Statement of Profit or loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash flows of the Company for the half year ended December 31, 2025, are enclosed as annexures.

Yours Sincerely,



Ghulam Dastgeer
Company Secretary

Cc:

Executive Director/HOD, Offsite-II, Department
Supervision Division, Securities & Exchange Commission of Pakistan



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk



Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2025

	Three month ended		Six Month Ended	
	December 31, 2025	December 31, 2024	December 31, 2025	December 31, 2024
	-----Rupees-----			
Sales- Net	4,332,566,300	3,534,432,320	7,702,813,971	6,759,077,137
Cost of Sales	(3,375,011,750)	(2,995,298,629)	(6,226,285,799)	(5,791,430,427)
Gross Profit	957,554,550	539,133,691	1,476,528,172	967,646,710
Administrative Expenses	61,657,234	58,249,282	111,846,122	104,646,213
Selling Expenses	69,460,037	43,131,925	117,889,734	83,827,444
	(131,117,271)	(101,381,207)	(229,735,856)	(188,473,657)
Operating Profit	826,437,279	437,752,484	1,246,792,316	779,173,053
Financial (Cost) /Income	(80,824,574)	(67,868,191)	(202,016,078)	(132,441,809)
	745,612,704	369,884,293	1,044,776,237	646,731,244
Other Income/(Loss)	28,027,203	50,423,119	56,793,299	142,644,938
	773,639,907	420,307,412	1,101,569,536	789,376,182
Other Expenses	(49,946,540)	(26,133,137)	(75,597,910)	(54,904,003)
Profit before income taxes and final taxes	723,693,367	394,174,275	1,025,971,626	734,472,179
Taxation - Final taxes	-	-	-	(4,004)
Profit before income tax	723,693,367	394,174,275	1,025,971,626	734,468,175
Taxation - Income tax	(319,359,183)	(137,195,683)	(417,946,569)	(275,996,570)
Profit after income tax	404,334,184	256,978,592	608,025,057	458,471,605
Earnings per share (EPS)				
- Basic and Diluted	1.77	1.12	2.66	2.01



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk



Citi Pharma Limited

**CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT DECEMBER 31, 2025**

	December 31, 2025 (Un-audited)	June 30, 2025 (Audited)
	-----Rupees-----	
EQUITY AND LIABILITIES		
SHARE CAPITAL AND RESERVES		
Authorized Capital:		
300,000,000 Ordinary shares of Rs. 10/ each	3,000,000,000	3,000,000,000
Share Capital		
Issued, subscribed and paid up capital	2,284,612,000	2,284,612,000
Capital Reserves		
Share Premium	1,391,532,000	1,391,532,000
Revaluation Surplus On Land	5,384,617,300	5,384,617,300
	6,776,149,300	6,776,149,300
Revenue Reserve		
Unappropriated Profit	1,615,228,237	1,806,817,381
	10,675,989,537	10,867,578,681
NON-CURRENT LIABILITIES		
Long Term Financing - Secured	38,714,500	-
Deferred Liabilities	213,971,698	201,763,862
Lease Liabilities	60,241,027	64,864,123
	312,927,225	266,627,986
CURRENT LIABILITIES		
Trade and Other Payables	3,821,252,101	3,858,531,251
Due to Related Parties	-	5,686,383
Short Term Borrowings	5,517,331,548	2,863,211,696
Current Portion of Long Term Liabilities-Secured	53,630,673	15,802,536
Dividend Payable	5,513,747	4,065,868
Accrued Mark Up	70,528,475	38,268,523
Provision For Taxation	407,858,153	519,677,557
	9,876,114,696	7,305,243,814
Contingencies and Commitments	-	-
TOTAL EQUITY AND LIABILITIES	20,865,031,459	18,439,450,481
ASSETS		
NON CURRENT ASSETS		
Property, Plant and Equipment	8,663,825,562	8,687,898,852
Long Term Security Deposits	27,618,117	25,443,117
Long Term Advance	254,540,900	254,540,900
	8,945,984,579	8,967,882,869
CURRENT ASSETS		
Stock in Trade	3,847,500,326	3,929,701,530
Trade Debts- Unsecured	4,020,453,306	3,078,215,648
Advances Deposits, Prepayments and Other Receivables	931,930,655	903,708,936
Short Term Investments	325,271,198	956,388,685
Cash And Bank Balances	2,793,891,395	603,552,814
	11,919,046,880	9,471,567,612
TOTAL ASSETS	20,865,031,459	18,439,450,481



588 - Q, Johar Town, Lahore - Pakisatn



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk



Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2025

	Note	Three month ended		Six Month Ended	
		December 31, 2025	December 31, 2024	December 31, 2025	December 31, 2024
		-----Rupees-----			
Profit for the period		404,334,184	256,978,592	608,025,057	458,471,605
Other comprehensive income for the period		-	-	-	-
Item that will not be reclassified subsequently to Profit or Loss					
Revaluation Surplus on Land		-	-	-	-
Total comprehensive income for the Period		404,334,184	256,978,592	608,025,057	458,471,605



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk



Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2025

PARTICULARS	SHARE CAPITAL	SHARE PREMIUM	REVENUE RESERVES	REVALUATION SURPLUS	TOTAL
----- Rupees -----					
Balance as at June 30, 2024	2,284,612,000	1,391,532,000	1,647,690,917	309,294,525	5,633,129,442
Total Comprehensive Income for the six months					
Final Dividend Paid for the year ended June 30, 2024 @ 32.5%	-	-	(742,498,902)	-	(742,498,902)
Profit for the period	-	-	458,471,605	-	458,471,605
Other comprehensive income	-	-	-	-	-
Balance as at December 31, 2024	2,284,612,000	1,391,532,000	1,363,663,620	309,294,525	5,349,102,145
Balance as at June 30, 2025	2,284,612,000	1,391,532,000	1,806,817,381	5,384,617,300	10,867,578,681
Total Comprehensive Income for the six months					
Final Dividend Paid for the year ended June 30, 2025 @ 35%	-	-	(799,614,200)	-	(799,614,200)
Profit for the period	-	-	608,025,057	-	608,025,057
Other comprehensive income	-	-	-	-	-
Balance as at December 31, 2025	2,284,612,000	1,391,532,000	1,615,228,237	5,384,617,300	10,675,989,537



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk




Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2025

December 31, 2025 December 31, 2024
-----Rupees-----

CASH FLOW FROM OPEARTING ACTIVITIES			
Profit Before Taxation for the period		1,025,971,626	734,472,179
Adjustments For Non- Cash Items And Other Line Items:			
Depreciation		103,152,429	62,651,852
Financial Charges		202,016,078	132,441,809
Accrued Interest Income		-	(6,532,860)
Unrealized Gain/Loss on Investment in Shares		(105,000)	-
Amortization and Extinguishment of Deferred Grant		-	(582,494)
Worker's Profit Participation Fund		55,078,477	39,429,559
Worker's Welfare Fund		20,519,433	14,689,444
		380,661,417	242,097,310
Profit/ (Loss) before working capital changes		1,406,633,043	976,569,490
Effect of working capital changes			
Advances, Deposits And Prepayments		(125,458,940)	(1,100,591)
Trade Debts		(942,237,658)	(757,021,429)
Stock In Trade		82,201,204	(643,037,014)
Trade And Other Payables		(40,265,636)	1,291,915,862
		(1,025,761,030)	(109,243,172)
Financial Charges Paid		(169,756,126)	(141,632,661)
Income Tax Paid		(422,869,334)	(318,075,328)
Gratuity Paid		-	-
Worker's Profit Participation Fund		(72,611,424)	(68,780,302)
		(665,236,884)	(528,488,291)
Net cash flow from operating activities	A	(284,364,870)	338,838,027
CASH FLOW FROM INVESTING ACTIVITIES			
Purchase Of Property, Plant & Equipment		(39,953,122)	(37,584,614)
Paid for Capital Work in Progress		(39,126,018)	(108,750,268)
Paid for Long Term Security Deposits		(2,175,000)	(8,168,141)
Short Term Investments		63,239,575	105,100,400
Net cash flow from investing activities	B	(18,014,565)	(49,402,623)
CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds less repayment of Long Term Financing		77,429,000	(12,859,000)
Due to Related Parties		(5,686,382)	198,240,000
Lease Rentals Paid		(886,363)	(2,856,215)
Dividend Paid		(798,166,321)	(741,386,649)
Short Term Borrowings		2,654,119,852	161,055,184
Net Cash flow From Investing Activities	C	1,926,809,784	(397,806,680)
Net Increase/ (decrease) in cash and cash equivalents	A+B+C	1,624,430,349	(108,371,276)
Cash and cash equivalents at beginning of the period		1,491,472,244	1,278,333,631
Cash and cash equivalents at end of the period		3,115,902,593	1,169,962,355
Cash and cash equivalents compromise of:			
Cash in hand		796,898	2,433,026
Cash at banks		2,793,094,497	69,368,520
Short Term Investments		322,011,198	1,098,160,809
		3,115,902,593	1,169,962,355



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk